The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Blood

• Publication date

  2012-01-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood-2011-06-357038PMID 22021371
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Conflict of interest disclosures

  2010cited by this paper
• Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells.

  2010cited by this paper
• Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma

  2010cited by this paper
• A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma.

  2010cited by this paper
• Relapsed multiple myeloma.

  2010cited by this paper
• Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

  2009cited by this paper
• International Myeloma Working Group molecular classification of multiple myeloma: spotlight review

  2009cited by this paper
• Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.

  2009cited by this paper
• Treatment of relapsed/refractory multiple myeloma.

  2009cited by this paper
• Eight‐year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1

  2008cited by this paper
• A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma.

  2008cited by this paper
• Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.

  2008cited by this paper
• Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.

  2008cited by this paper
• Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.

  2008influential reference
• International uniform response criteria for multiple myeloma

  2007cited by this paper
• An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma

  2007cited by this paper
• VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study Group.

  2007cited by this paper
• A systematic review of phase‐II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma

  2006cited by this paper
• Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.

  2006cited by this paper
• International uniform response criteria for multiple myeloma

  2006cited by this paper
• Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.

  2006cited by this paper
• Thalidomide and hematopoietic-cell transplantation for multiple myeloma.

  2006cited by this paper
• Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma

  2006cited by this paper
• International uniform response criteria for multiple myeloma

  2006cited by this paper
• Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.

  2000cited by this paper
• CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION

  1998cited by this paper
• A mathematical model relating response durations to amount of subclinical resistant disease.

  1991cited by this paper
• Adjusting survival curves for imbalances in prognostic factors.

  1988cited by this paper

• Real-world outcomes of maintenance therapy post-autologous stem cell transplantation in newly diagnosed multiple myeloma

  2025cites this paper
• Survival Outcomes After Front-Line Consolidation With High-Dose Melphalan and Autologous Stem Cell Transplantation in Younger and Elderly Multiple Myeloma Patients: A Retrospective Bi-Centric Analysis.

  2025cites this paper
• Singapore Myeloma Study Group consensus guidelines for the management of patients with newly diagnosed multiple myeloma.

  2025cites this paper
• Maintenance therapy after ASCT in newly diagnosed multiple myeloma patients: single agent versus combination drugs

  2025cites this paper
• Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.

  2024cites this paper
• Role of Consolidation and Maintenance.

  2024cites this paper
• The role of maintenance therapy following autologous stem cell transplantation in newly diagnosed multiple myeloma: Considerations on behalf of the Chronic Malignancies Working Party of the EBMT

  2024cites this paper
• LENALIDOMIDE AND DEXAMETHASONE WITH OR WITHOUT IXAZOMIB MAINTENANCE TAILORED BY RESIDUAL DISEASE STATUS IN MYELOMA.

  2023cites this paper
• Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial

  2023cites this paper
• Cellular immunity in the era of modern multiple myeloma therapy

  2023cites this paper
• Lenalidomide or bortezomib as maintenance treatment remedy the inferior impact of high-risk cytogenetic abnormalities in non-transplant patients with newly diagnosed multiple myeloma: a real-world multi-centered study in China

  2023cites this paper
• Newly diagnosed multiple myeloma: making sense of the menu.

  2022cites this paper
• Clinical trials: design, endpoints and interpretation of outcomes

  2022cites this paper
• Anti‐CD19 and anti‐BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem‐cell transplantation for high‐risk newly diagnosed multiple myeloma

  2022cites this paper
• A review of the current status of lenalidomide maintenance therapy in multiple myeloma in 2022

  2022cites this paper
• Impact of autologous transplantation on survival in patients with newly diagnosed multiple myeloma who have high‐risk cytogenetics: A meta‐analysis of randomized controlled trials

  2022cites this paper
• What’s Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma

  2022cites this paper
• Immunomodulators in newly diagnosed multiple myeloma: current and future concepts

  2021cites this paper
• Reply to G. R. Mohyuddin et al and A. Garfall et al.

  2021cites this paper
• Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple Myeloma.

  2021cites this paper
• Early versus Late Discontinuation of Maintenance Therapy in Multiple Myeloma

  2021cites this paper
• MUKnine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia

  2021cites this paper
• Current approaches to management of high‐risk multiple myeloma

  2021influential citation
• Evolution of Treatment Paradigms in Newly Diagnosed Multiple Myeloma

  2021cites this paper
• Propensity-Score Matched Analysis of the E�cacy of Maintenance/Continuous Therapy in Newly Diagnosed Patients With Multiple Myeloma: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma

  2021cites this paper
• Future Directions in Maintenance Therapy in Multiple Myeloma

  2021cites this paper
• Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline

  2021cites this paper
• Significance of maintenance therapy after HDT/ASCT in symptomatic multiple myeloma: A multicenter retrospective analysis in Kansai Myeloma Forum

  2021cites this paper
• Phase II Trial of Maintenance Treatment With IL2 and Zoledronate in Multiple Myeloma After Bone Marrow Transplantation: Biological and Clinical Results

  2021cites this paper
• The evolving role and utility of off-label drug use in multiple myeloma

  2021cites this paper
• Limited benefits of thalidomide and dexamethasone maintenance after autologous stem cell transplantation in newly diagnosed multiple myeloma patients: a prospective phase II multi-center study in Korea.

  2021cites this paper
• Safety of lenalidomide for maintenance treatment of patients with multiple myeloma following autologous stem cell transplantation

  2021cites this paper
• Post-Transplant Maintenance Treatment Options in Multiple Myeloma

  2021cites this paper
• Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma Myeloma

  2021cites this paper
• Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma

  2021cites this paper
• Current diagnosis, risk stratification and treatment paradigms in newly diagnosed multiple myeloma.

  2021cites this paper
• Rapid Progress in the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma

  2021cites this paper
• Efficacy of proteasome inhibitor‐based maintenance following autologous transplantation in multiple myeloma: A systematic review and meta‐analysis

  2020cites this paper
• Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open‐label, randomised, Phase III trial

  2020cites this paper
• Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study

  2020cites this paper
• Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma

  2020cites this paper
• Evolution of diagnostic workup and treatment for multiple myeloma 2013‐2019

  2020cites this paper
• Maintenance Therapy

  2020cites this paper
• Current and future perspectives of maintenance therapy in multiple myeloma.

  2020cites this paper
• Protocolo de tratamento do mieloma múltiplo: serviço de hematologia Hospital Universitário Walter Cantídio, abril - 2019

  2020cites this paper
• Thrombosis in Patients with Myeloma Treated in the Myeloma IX and Myeloma XI Phase III Randomized Controlled Trials.

  2020cites this paper
• Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma

  2020cites this paper
• Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial

  2020cites this paper
• Autologous Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Therapies.

  2020cites this paper
• Advances in maintenance strategy in newly diagnosed multiple myeloma patients eligible for autologous transplantation

  2020cites this paper
• Evolution or revolution in multiple myeloma therapy and the role of the UK

  2020cites this paper
• Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial.

  2020cites this paper
• Efficacy of VRD（Bortezomib, Lenalidomide, and Dexamethasone) Consolidation Therapy and Maintenance Therapy with Immunomodulatory Drugs（Thalidomide or Lenalidomide) after Autologous Peripheral Blood Stem Cell Transplantation in the Era of Bortezomib-Containing Induction Therapy―A Single Institution E

  2020cites this paper
• Newly Diagnosed Myeloma in 2020.

  2020cites this paper
• Blockade of HSP70 by VER-155008 synergistically enhances bortezomib-induced cytotoxicity in multiple myeloma

  2020cites this paper
• Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future.

  2020cites this paper
• Approaching the first relapse after autologous transplant in multiple myeloma

  2020cites this paper
• Clinical Trial Outcomes: What Matters to Patients.

  2019cites this paper
• Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study

  2019cites this paper
• Risk adapted post-transplant maintenance in multiple myeloma

  2019cites this paper
• Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

  2019cites this paper
• Mechanism of Action and Novel IMiD-Based Compounds and Combinations in Multiple Myeloma

  2019cites this paper
• A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study

  2019cites this paper
• Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma: Long-term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial.

  2019cites this paper
• Stem-cell transplantation in multiple myeloma: how far have we come?

  2019cites this paper
• The role and value of maintenance therapy following autologous stem cell transplant in multiple myeloma

  2019cites this paper
• Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma

  2019cites this paper
• Moving Toward Continuous Therapy in Multiple Myeloma

  2019influential citation
• Current status of autologous stem cell transplantation for multiple myeloma

  2019cites this paper
• Immunomodulatory drugs in the treatment of multiple myeloma.

  2019cites this paper
• Intermittent Low-Dose Thalidomide Plus Dexamethasone as Maintenance Therapy in Patients with Multiple Myeloma

  2019cites this paper
• The Impact of Performing a Network Meta-Analysis with Imperfect Evidence

  2019cites this paper
• Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12)

  2019cites this paper
• Assessing the impact of a matching‐adjusted indirect comparison in a Bayesian network meta‐analysis

  2019cites this paper
• Post-Transplantation Management Strategies

  2018cites this paper
• Ixazomib: a novel drug for multiple myeloma

  2018cites this paper
• Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial.

  2018cites this paper
• Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study

  2018cites this paper
• Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma

  2018cites this paper
• Thalidomide for myeloma: still here?

  2018cites this paper
• Prognostic factors for multiple myeloma in the era of novel therapies

  2018cites this paper
• Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement

  2018cites this paper
• How I treat the young patient with multiple myeloma.

  2018cites this paper
• Determining treatment intensity in elderly patients with multiple myeloma

  2018cites this paper
• Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials

  2018cites this paper
• Multiple Myeloma: Front Line Therapy and Autologous Stem Cell Transplantation

  2018cites this paper
• Maintenance and continuous therapy for multiple myeloma

  2018cites this paper
• Nowe terapie w leczeniu szpiczaka z wysokim ryzykiem cytogenetycznym

  2018cites this paper
• Implementation of a pharmacy-managed program for the transition of chemotherapy to the outpatient setting.

  2018cites this paper
• Treatment of Transplant Eligible Patients with Multiple Myeloma

  2018cites this paper
• Long-Term Efficacy of Maintenance Therapy for Multiple Myeloma: A Quantitative Synthesis of 22 Randomized Controlled Trials

  2018influential citation
• Treatment of t(4;14) and del(17p) in multiple myeloma

  2018cites this paper
• High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes

  2018cites this paper
• Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis

  2018cites this paper
• Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients

  2018cites this paper
• A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

  2018cites this paper
• Health related quality of life for multiple myeloma patients according to treatment strategy after autologous stem cell transplant: a cross-sectional study using EORTC, EQ-5D and MY-20 scales

  2018cites this paper
• Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial

  2017cites this paper
• Posttransplant maintenance therapy in multiple myeloma: the changing landscape

  2017cites this paper
• Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist

  2017cites this paper